![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Ritonavir boosting of low-dose danoprevir (RG7227; ITMN-191), HCV NS3/4A protease inhibitor, results in robust reduction in HCV RNA at lower exposures than provided by unboosted regimens
|
|
|
Reported by Jules Levin
EASL Apr 14-18 2010
Vienna Austria
Auckland Clinical Studies, Auckland, New Zealand; CENTRE CAP, France; Christchurch Clinical Studies Trust, Christchurch, New Zealand; Department of Hepatology and Immunodeficiencies, Warsaw Medical University, Poland; Warsaw Medical University & Hospital of Infectious Diseases, Warsaw, Poland; Roche, USA
![](../images/041510/041510-6/image002.gif)
![](../images/041510/041510-6/image004.gif)
![](../images/041510/041510-6/image006.gif)
CYP3A = cytochrome P450 3A
![](../images/041510/041510-6/image008.gif)
"Figure description: An unboosted high dose of a rapidly cleared compound requires a high AUC and a Cmax to achieve an acceptable trough concentration. With RTV boosting, it is possible for a much lower dose to provide a superior trough concentration, even while overall exposure and Cmax are reduced"
![](../images/041510/041510-6/image010.gif)
![](../images/041510/041510-6/image012.gif)
![](../images/041510/041510-6/image014.gif)
![](../images/041510/041510-6/image016.gif)
![](../images/041510/041510-6/image018.gif)
![](../images/041510/041510-6/image020.gif)
![](../images/041510/041510-6/image022.gif)
![](../images/041510/041510-6/image024.gif)
![](../images/041510/041510-6/image026.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|